Pazopanib, a small molecule inhibitor of VEGFR, PDGFR, and KIT, has previously been assessed for antitumor activity in ACC patients with underwhelming results, including 1 of 46 patients demonstrating a partial response and 35 of 46 with stable disease [24]. Here, PDGFRB is linked to adrenal cortex carcinoma.